Anti-idiotype antibody vaccine therapies of cancer.
Anti-idiotype antibody vaccine therapies of cancer.
复制标题
癌症的抗独特型抗体疫苗疗法。
DOI：
10.1007/978-1-4615-6189-7_4
复制
发表时间：
1998
影响因子：
--
通讯作者：
Foon,KA
中科院分区：
文献类型：
--
作者：
Bhattacharya-Chatterjee,M;Foon,KA
癌症的免疫治疗分为两个重叠的类别：主动和被动。主动免疫治疗的目的是刺激宿主抗肿瘤免疫，无论是细胞免疫还是体液免疫。这可以通过使用肿瘤疫苗产生对肿瘤相关抗原（TAAs）的免疫反应，以直接或特定的方式实现。非特异性抗肿瘤免疫可通过卡介苗（BCG）等化合物传播。被动免疫治疗依赖于具有先天抗肿瘤特性的生物活性药物的施用，例如与生长因子受体反应的抗体。在大多数情况下，宿主免疫是主动免疫治疗的重要辅助因素。此外，一些药物，如抗体，可以发挥由这些疗法启动的抗免疫回路，并解释了不完美但仍然有用的主动和被动类型的划分。免疫疗法在某些动物模型系统中非常有效，几十年来一直用于治疗人类癌症。许多研究者已经研究了肿瘤源性物质对癌症患者的主动免疫治疗，并报道了积极的临床反应。使用肿瘤材料进行免疫存在许多问题，并且经常发现T抗原的免疫原性很差。对缺乏抗肿瘤免疫的一种常见解释是免疫系统已被肿瘤抗原耐受。如果这是真的，就可以采取措施打破现有的抗肿瘤耐受性。打破耐受性的有效方法是在不同的分子环境中将关键表位呈现给耐受性宿主[2]。虽然这对半抗原和其他小的、定义明确的抗原很容易做到，但对大多数肿瘤抗原却不可能做到，因为它们在化学上定义不清，难以纯化——尤其是碳水化合物抗原，它们的疫苗不能通过重组技术生产。免疫网络假说提供了一种独特的方法，将表位结构转化为在抗体表面表达的独特型Id决定因子。免疫球蛋白（Ig）分子具有抗原识别特异性的可变区域。可变区由Vh、D和JH基因编码
Immunotherapy of cancer is divided into two overlapping categories: active and passive. The goal of active immunotherapy is the stimulation of host antitumor immunity, either cellular or humoral. This can be accomplished in a direct or specific fashion by using tumor vaccines to generate an immune response to tumor-associated antigens (TAAs). Nonspecific antitumor immunity can be propagated by compounds such as bacillus Calmette-Guerin (BCG). Passive immunotherapy relies on the administration of biologically active agents with innate antitumor properties, such as antibodies reactive with growth factor receptors. In most instances, host immunity is an important cofactor in active immunotherapy. In addition, some agents, such as antibodies, can exert anti-immune circuits that are set into motion by these therapies and account for the imperfect but nonetheless useful division into active and passive types.Immunotherapy is very effective in certain animal model systems, and it has been used to treat human cancers for several decades [1]. The active immunotherapy of cancer patients with tumor-derived material has been studied by numerous investigators, with positive clinical responses reported. A number of problems exist with using tumor material for immunization, and T AAs are often found to be poorly immunogenic. A common explanation for the absence of antitumor immunity is that the immune system has been tolerized by the tumor antigen. If this is true, steps could be taken to break the existing antitumor tolerance. An effective method of breaking tolerance is to present the critical epitope in a different molecular environment to the tolerized host [2]. While this can be done easily with haptens and other small, well-defined antigens, it is impossible with most tumor antigens because they are chemically ill defined and difficult to purify-especially carbohydrate antigens, vaccines for which cannot be produced by recombinant techniques. The immune network hypothesis offers a unique approach to transform epitope structures into idiotypic Id determinants expressed on the surface of antibodies. Immunoglobulin (Ig) molecules possess variable regions specific for antigen recognition. The variable region is encoded by Vh, D, and JH genes
登录
查看更多内容
独特型/粒细胞-巨噬细胞集落刺激因子融合蛋白作为 B 细胞淋巴瘤疫苗
影响因子：
64.8
作者：
M. Tao;R. Levy
通讯作者：
R. Levy
抗独特型肿瘤疫苗。
影响因子：
--
作者：
Bhattacharya-Chatterjee,M;Kohler,H
通讯作者：
Kohler,H
独特型免疫诱导对突变 p53 的免疫力和肿瘤排斥
DOI：
--
发表时间：
1998
期刊：
Nature Network Boston
影响因子：
--
作者：
P. Ruiz;R. Wolkowicz;A. Waisman;D. Hirschberg;P. Carmi;Netta Erez;H. Garren;J. Herkel;M. Karpuj;L. Steinman;V. Rotter;I. Cohen
通讯作者：
I. Cohen
牛血清白蛋白耐受家兔对注射其他异源血清白蛋白的免疫反应
影响因子：
15.3
作者：
W. Weigle
通讯作者：
W. Weigle
DOI：
10.1200/jco.2000.18.2.376
发表时间：
2000
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
K. Foon;J. Lutzky;R. Baral;J. Yannelli;L. Hutchins;A. Teitelbaum;O. Kashala;Ruma Das;Juanita Garrison;R. Reisfeld;M. Bhattacharya‐Chatterjee
通讯作者：
K. Foon;J. Lutzky;R. Baral;J. Yannelli;L. Hutchins;A. Teitelbaum;O. Kashala;Ruma Das;Juanita Garrison;R. Reisfeld;M. Bhattacharya‐Chatterjee